AstraZeneca buys Alexion Pharmaceuticals for $39bn

It is the largest deal in AstraZeneca’s history, and the third-largest deal of 2020.

It is the largest deal in AstraZeneca’s history, and the third-largest deal of 2020.

In the largest pharmaceutical deal of the year, British pharmaceutical giant AstraZeneca has acquired American biotech firm and rare diseases specialist Alexion for $39 billion.

Though it pales in comparison to last year’s jumbo pharma deals – Bristol-Myers Squibb acquired Celgene for $74 billion, and AbbVie bought Allergan for $63 billion – it is nonetheless a highly significant play for AstraZeneca, and likely to help defend the firm from hostile takeovers by the likes of Pfizer, which almost bought the company out six years ago.

After fending off the takeover bid by pledging to radically improve its research and development (R&D) operation, AstraZeneca struggled for a few years before a series of acquisitions of high-performing cancer drugs boosted its stock price. The reversal of its fortunes arguably began in 2016, when it moved its headquarters from Cheshire in northwestern England to Cambridge, giving it access to the local university’s brainy research graduates.

Its latest acquisition came at a high price: investors baulked at the 45% premium AstraZeneca paid for Alexion. But AstraZeneca’s CEO Pascal Soriot is betting on Alexion’s 11-drug pipeline in combatting diseases that affect the “complement system” – a part of the immune system that helps antibodies and white blood cells clear microbes and attack pathogen cell membranes.

Soriot believes the acquisition will help develop AstraZeneca’s ability to use genomics to target rare diseases, and globalize Alexion’s portfolio into emerging markets and China.

The deal would be the second time Alexion CEO Ludwig Hantson oversees the sale of a company he runs; the first time was only four years ago, when Baxalta was acquired by Shire for $32 billion.


Legal advisor to AstraZeneca: Freshfields Bruckhaus Deringer

Financial advisor to AstraZeneca: Evercore Partners, Centerview Partners

Legal advisor to Alexion: Wachtell, Lipton, Rosen & Katz

Financial advisor to Alexion: BofA Securities


Arjun Sajip

Read the full Special Report: UK: A Centre of Legal Excellence

The UK's sophisticated economy has many drivers, with the financial and professional services industries as two of its pillars. Its legal sector stands out as world class and is relied upon not just by domestic businesses, but also by companies and individuals the world over.
Summary An American law firm in London: Cravath, Swaine & Moore explains its positioning Livingbridge invests in Visualsoft UK-based GHO Capital Partners increases investment in Envision Pharma Group Private equity firm Endless buys UK's Hovis Bowmark Capital backs buy-out of Totalmobile The Carlyle Group acquires UK developer Beechcroft Shore Capital acts as nominated adviser on £20m Helios equity raise CGE Partners invests in Aurora Energy Research Countrywide set to undergo recapitalisation with funds from Alchemy Partners

Read the full Special Report: USA: Global Powerhouse

In a world where the only thing that doesn't change is change itself, opportunities and risks are too obvious to ignore, and the legal market is no exception. Worth over $400 billion and one of the most profitable in the world, the U.S. legal industry is under fundamental transformation. Whether you're an in-house counsel or a law firm, only those with far-ranging sights, clear thoughts and quick action can survive and thrive.
Summary Interview: Prakash Melwani (Chief Investment Officer, Blackstone) Salesforce buys Slack for $27.7bn S&P Global buys IHS Markit for $44bn The Home Depot re-buys HD Supply for $9.1 billion PNC buys BBVA's US arm for $11.6bn “External consultants bring more cost-efficiency and innovation than internal marketing teams” Advanced Micro Devices buys Xilinx for $35bn Leading the way: Kamala Harris makes history What would a Biden presidency mean for the US and the world?


Accenture's CEO and CFO interview by Leaders League Group

About us


Ce site utilise des cookies. En continuant la navigation, vous acceptez nos conditions d'utilisation des cookies.
Plus d'informations